IMPORTANCESeveral studies were conducted to estimate the average incubation period of COVID-19; however, the incubation period of COVID-19 caused by different SARS-CoV-2 variants is not well described. OBJECTIVE To systematically assess the incubation period of COVID-19 and the incubation periods of COVID-19 caused by different SARS-CoV-2 variants in published studies.
Background Zika virus (ZIKV) infection has potential result in severe birth effects. An improved understanding of global trend and regional differences is needed. Methods Annual ZIKV infection episodes and incidence rates were collected from Global Burden of Disease Study 2019. Episodes changes and estimated annual percentage changes (EAPCs) of age-standardized incidence rate (ASR) were calculated. Top passenger airport-pairs were obtained from the International Air Transport Association to understand places susceptible to imported ZIKV cases. Results Globally, the ASR increased by an average of 72.85% (95%CI: 16.47% to 156.53%) per year from 2011 to 2015 and subsequently decreased from 20.25 per 100,000 in 2015 to 3.44 per 100,000 in 2019. Most of ZIKV infections clustered in Latin America. The proportion of episodes in Central and Tropical Latin America decreased in 2019 with sporadic episodes elsewhere. High Socio-Demographic Index (SDI) regions had more episodes in 2019 than in 2015. Additionally, 15–49 years group had the largest proportion of episodes, females had a higher number of episodes, and a higher incidence rate of 70 plus group was observed in males than females. Certain cities in Europe, North America and Latin America/Caribbean had a high population mobility in ZIKV outbreak areas considered a high risk of imported cases. Conclusions ZIKV infection is still a public health threat in Latin America and Caribbean and high SDI regions suffered an increasing trend of ZIKV infection. Interventions such as development of surveillance networks and vector-control should be attached to ZIKV control in these key regions. Reproductive suggestions should be taken to reduce ZIKV-related birth defects for the people of reproductive age who are facing a higher threat of ZIKV infection, especially females. Moreover, surveillance of travellers is needed to reverse the uptrends of travel-related imported ZIKV infection. More studies focusing on ZIKV should be performed to make targeted and effective prevention strategies in the future.
Nonpharmaceutical interventions to limit the coronavirus disease 2019 (COVID‐19) pandemic might reduce the transmission of influenza viruses and disrupt the typical seasonality of influenza. However, changes in epidemiology and seasonal patterns of influenza remain unknown in China during the COVID‐19 pandemic. Data on influenza‐like illness (ILI) and influenza cases between surveillance Week 14 in 2010 and Week 6 in 2023 and ILI outbreaks between Week 14 in 2013 and Week 6 in 2023 were collected from the weekly reports of the Chinese National Influenza Center. A total of 32 10 735 ILI specimens were tested between Week 14 in 2010 and Week 6 in 2023 in China, with 12.4% of specimens positive for influenza. The influenza‐positive percentage ranged from 11.8% to 21.1% in southern China and 9.5% to 19.5% in northern China between the 2010/2011 and 2019/2020 influenza seasons. The influenza‐positive percentage was 0.7% in southern China and 0.2% in northern China in the 2020/2021 season. An increasing trend in influenza‐positive percentage was observed in southern China in Weeks 18–27 in the 2022/2023 season, with a peak of 37.3%. A total of 768 ILI outbreaks reported in southern China in Weeks 14–26 in the 2022/2023 season were much more than those in the same period in the 2020/2021 and 2021/2022 seasons. In summary, seasonal influenza shifted from low to out‐of‐season epidemics during the COVID‐19 pandemic in China, especially in southern China. Influenza vaccination and everyday preventive actions, such as mask wearing, appropriate air exchange, and good hand hygiene practices, are essential for the prevention of influenza virus infection during the COVID‐19 pandemic.
Background. COVID-19 prevention and control measures might affect influenza epidemic in China since the nonpharmaceutical interventions (NPIs) and behavioral changes contain transmission of both SARS-CoV-2 and influenza virus. We aimed to explore the impact of COVID-19 prevention and control measures on influenza using data from the National Influenza Surveillance Network. Methods. The percentage of influenza-like illness (ILI%) in southern and northern China from 2010 to 2022 was collected from the National Influenza Surveillance Network. Weekly ILI% observed value from 2010 to 2019 was used to calculate estimated annual percentage change (EAPC) of ILI% with 95% confidence intervals (CIs). Time series analysis was applied to estimate weekly ILI% predicted values in 2020/2021 and 2021/2022 season. Impact index was used to explore the impact of COVID-19 prevention and control on influenza during nonpharmaceutical intervention and vaccination stages. Results. China influenza activity was affected by the COVID-19 pandemic and different prevention and control measures during 2020-2022. In 2020/2021 season, weekly ILI% observed value in both southern and northern China was at a low epidemic level, and there was no obvious epidemic peak in winter and spring. In 2021/2022 season, weekly ILI% observed value in southern and northern China showed a small peak in summer and epidemic peak in winter and spring. The weekly ILI% observed value was generally lower than the predicted value in southern and northern China during 2020-2022. The median of impact index of weekly ILI% was 15.11% in north and 22.37% in south in 2020/2021 season and decreased significantly to 2.20% in north and 3.89% in south in 2021/2022 season. Conclusion. In summary, there was a significant decrease in reported ILI in China during the 2020-2022 COVID-19 pandemic, particularly in winter and spring. Reduction of influenza virus infection might relate to everyday Chinese public health COVID-19 interventions. The confirmation of this relationship depends on future studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.